跳至主要内容
临床试验/NCT06386172
NCT06386172已完成不适用

An Electronic Triggering Decision-support System to Improve Detection, Management and Nephrologist Referral of Patients With Chronic Kidney Disease in Primary Care: A Pragmatic Cluster Randomized Controlled Trial

Karolinska Institutet1 个研究点 分布在 1 个国家目标入组 65 人开始时间: 2023年9月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
65
试验地点
1
主要终点
Number of participants screened for creatinine and albuminuria

研究概览

简要总结

One in 10 adults in Region Stockholm have chronic kidney disease (CKD), which dramatically increases healthcare costs and the risk of medication errors or adverse health outcomes, including cardiovascular disease and death. Identification and early management of these patients is done in primary care settings. However, most adults with CKD in our region are under detected, undiagnosed and undertreated, with low rates of referral to nephrology-specialist care.

This is a pragmatic cluster randomized controlled trial (RCT) involving 66 primary healthcare centers in Region Stockholm, and testing the effect of an electronic clinical decision support (CDS) triggering system to assist general practitioners through the guideline-recommended processes of CKD care.

The centers, providing healthcare to approximately 780.000 citizens, will be randomized 50:50 to this CDS trigger (vs basic advice) for 18 months. Study outcomes will consider the improvement in the indicators of CKD care.

As a pragmatic trial there is no active recruitment or active data collection. The trial is embedded into the ongoing Stockholm CREAtinine Measurements (SCREAM) project, a database collection of healthcare use for the complete population of Stockholm. Using this real-world healthcare data collection, the investigators will be able to measure with precision the impact of our CDS trigger and its potential to improve clinical care.

详细描述

A large proportion of persons in our region suffer from CKD and are not adequately identified and cared for.

The hypothesis tested in this trial is that providing a structured framework of advice in the form of an electronic clinical decision support (CDS) triggering system to general practitioners has the potential to improve the identification, recognition and care of persons with CKD.

About 10% of adults in Stockholm suffer from CKD, a condition characterized by reduced kidney function or signs of kidney damage that are sustained over time. CKD is disproportionally present in older adults (in 18% of persons aged 66-74, and 41% of persons aged >75 years) and in those with non-communicable diseases like hypertension (in 29% of patients), diabetes (26%) and cardiovascular disease (37%).

CKD can be identified and diagnosed with two simple and inexpensive laboratory analyses:

  • serum/plasma creatinine, which serves to estimate glomerular filtration rate (eGFR) as a marker of kidney function,
  • and albumin in urine (albuminuria), which serves as a marker of kidney damage.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Single (Outcomes Assessor)

入排标准

性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Number of participants screened for creatinine and albuminuria

时间窗: Through study completion, an average of 18 months

The number of eligible persons (i.e with an indication for screening) screened for creatinine and albuminuria once annually. Patients eligible for screening are, according to current guidelines those with hypertension, diabetes or history of cardiovascular disease.

Number of screened participants with retesting for creatinine and albuminuria

时间窗: Through study completion, an average of 18 months

The re-testing of these labs within 3-6 months among people with abnormal eGFR (\<60 ml/min/1.73 m2) or albuminuria (\>30 mg/g) at screening.

次要结局

  • Number of participants referred to nephrologist care(Through study completion, an average of 18 months)
  • Number of participants with laboratory-determined CKD receiving a clinical diagnosis(Through study completion, an average of 18 months)
  • Number of participants receiving CKD-modifying agents(Through study completion, an average of 18 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Juan Jesus Carrero

Professor of Cardiorenal Epidemiology

Karolinska Institutet

研究点 (1)

Loading locations...

相似试验

Electronic Decision-support System to Improve... | 临床试验